Review of clinical applications of radiation-enhancing nanoparticles.
Cancer
Nanoparticles
Radiotherapy
Journal
Biotechnology reports (Amsterdam, Netherlands)
ISSN: 2215-017X
Titre abrégé: Biotechnol Rep (Amst)
Pays: Netherlands
ID NLM: 101637426
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
08
2020
revised:
13
10
2020
accepted:
27
10
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Clinical evidence of the radiation-enhancing effects of nanoparticles has emerged. We searched the literature in English and French on PubMed up to October 2019. The search term was "nanoparticle" AND "radiotherapy", yielding 1270 results. The two main NP used in clinical trials were hafnium oxide and gadolinium involving a total of 229 patients. Hafnium oxide NP were used in three phase 1/2 trials on sarcoma, head and neck squamous cell carcinoma or liver cancer and one phase 2/3 trial. There are six ongoing phase 1/2 clinical trials to evaluate the combination of gadolinium-based NP and RT for the treatment of brain metastases and cervical cancer. So far, intratumoral hafnium oxide nanoparticles were safe and improved efficacy in locally advanced sarcoma.
Identifiants
pubmed: 33204660
doi: 10.1016/j.btre.2020.e00548
pii: S2215-017X(20)30683-4
pmc: PMC7649452
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e00548Informations de copyright
© 2020 Published by Elsevier B.V.
Déclaration de conflit d'intérêts
NS, EC, CV: None SB: honorarium, travel grant, meeting grant, unrestricted grant for the phase 1/2 and phase 3 trials NBTXR3 in sarcoma CLT: Participation in advisory boards from Nanobiotix JT: personal fees from Nanobiotix VC: personal fees from Nanobiotix
Références
J Neurooncol. 2010 Jan;96(1):45-68
pubmed: 19960227
J Clin Oncol. 2006 Mar 10;24(8):1295-304
pubmed: 16525185
J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87
pubmed: 25313184
Cancer Lett. 2016 Jun 1;375(2):256-262
pubmed: 26987625
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
BMJ Open. 2019 Feb 11;9(2):e023591
pubmed: 30755445
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Theranostics. 2020 Jan 1;10(3):1319-1331
pubmed: 31938067
Radiother Oncol. 2019 Dec;141:262-266
pubmed: 31439450
Clin Oncol (R Coll Radiol). 2002 Jun;14(3):203-12
pubmed: 12109823
Lancet Oncol. 2019 Aug;20(8):1148-1159
pubmed: 31296491